Dr. Joel A. Kaplan, DO
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
NC license 2007-00310 -
Obstetrics & Gynecology Physician
NC license 2007-00310 -
Pediatrics Physician
NC license 2007-00310
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolinas Medical Center/behav Health Charlotte, NC
Medical groups
- Carolinas Medical Center (1,067 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $198 in total to this clinician.
| Y-mabs Therapeutics, Inc. | $120 |
|---|---|
| Uswm, LLC | $77.55 |
| Food and Beverage | $198 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,500 in research payments for these studies, mostly to the institutions running them.
- Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
AbbVie Inc. · Active, not recruiting · NCT05206357
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.